On Monday, Gossamer Bio Inc (NASDAQ: GOSS) opened higher 3.23% from the last session, before settling in for the closing price of $1.24. Price fluctuations for GOSS have ranged from $0.51 to $1.55 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted -168.69% at the time writing. With a float of $182.66 million, this company’s outstanding shares have now reached $227.22 million.
In an organization with 145 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 100.0%, operating margin of -43.96%, and the pretax margin is -40.41%.
Gossamer Bio Inc (GOSS) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Gossamer Bio Inc is 19.64%, while institutional ownership is 58.35%. The most recent insider transaction that took place on Jun 24 ’24, was worth 1,260. In this transaction Chief Medical Officer of this company sold 1,908 shares at a rate of $0.66, taking the stock ownership to the 196,891 shares. Before that another transaction happened on Jun 21 ’24, when Company’s President & CEO bought 372,000 for $0.67, making the entire transaction worth $250,282. This insider now owns 5,408,073 shares in total.
Gossamer Bio Inc (GOSS) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.18 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -168.69% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 15.97% during the next five years compared to 40.29% growth over the previous five years of trading.
Gossamer Bio Inc (NASDAQ: GOSS) Trading Performance Indicators
Check out the current performance indicators for Gossamer Bio Inc (GOSS). In the past quarter, the stock posted a quick ratio of 5.71. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.34.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.24, a number that is poised to hit -0.18 in the next quarter and is forecasted to reach -0.47 in one year’s time.
Technical Analysis of Gossamer Bio Inc (GOSS)
Let’s dig in a bit further. During the last 5-days, its volume was 1.39 million. That was inferior than the volume of 1.51 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 47.17%. Additionally, its Average True Range was 0.09.
During the past 100 days, Gossamer Bio Inc’s (GOSS) raw stochastic average was set at 65.82%, which indicates a significant increase from 65.52% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 53.61% in the past 14 days, which was lower than the 90.24% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.0568, while its 200-day Moving Average is $1.0066. However, in the short run, Gossamer Bio Inc’s stock first resistance to watch stands at $1.3500. Second resistance stands at $1.4200. The third major resistance level sits at $1.4800. If the price goes on to break the first support level at $1.2200, it is likely to go to the next support level at $1.1600. The third support level lies at $1.0900 if the price breaches the second support level.
Gossamer Bio Inc (NASDAQ: GOSS) Key Stats
There are currently 227,302K shares outstanding in the company with a market cap of 290.94 million. Presently, the company’s annual sales total 114,700 K according to its annual income of -56,530 K. Last quarter, the company’s sales amounted to 9,890 K and its income totaled -36,640 K.
